Orna Therapeutics Announces Presentation at the American Society of Gene and Cell Therapy Annual Meeting Supporting its in vivo CAR Therapy Approach in Autoimmune Diseases

On May 5, 2025 Orna Therapeutics, a biotechnology company dedicated to engineering immune cells in vivo to treat autoimmune and oncology diseases, reported an upcoming presentation at the 28th American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting being held May 13-17, 2025, in New Orleans, Louisiana (Press release, Orna Therapeutics, MAY 5, 2025, View Source [SID1234652516]). The presentation will highlight data supporting Orna’s in vivo CAR therapy approach in autoimmune diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to present new data at the upcoming ASGCT (Free ASGCT Whitepaper) annual meeting as we advance our panCAR programs towards the clinic," said Joseph Bolen, Ph.D., Chief Executive Officer of Orna Therapeutics. "Our platform, which pairs our circular (oRNA) technology and best-in-class lipid nanoparticle (LNP) delivery has the potential to deliver a pipeline in a product and treat multiple diseases and therapeutic areas. The data to be presented will highlight the ability of our platform to enable sustained pharmacodynamic effects at low doses, durable protein expression, and repeat dosing. We look forward to advancing our CD19 autoimmune panCAR program into the clinic in 2026, followed by our BCMA panCAR program in oncology."

Presentation details are as follows:

Title: In Vivo panCAR Therapy Using Circular RNA for the Treatment of Autoimmune Disease

Speaker: Megan Hoban, Ph.D., panCAR Program Lead, Orna Therapeutics

Date/Time: Thursday, May 15, 2025, 8:00 AM – 9:45 AM CDT

Session Name: Cellular and Gene Therapies for Autoimmune Disease

Location: Room 388-390

By leveraging its leading oRNA technology and potentially best-in-class LNP delivery, Orna’s in vivo CD19 panCAR platform holds the potential to benefit patients across multiple B cell driven autoimmune diseases. New data to be presented at ASGCT (Free ASGCT Whitepaper) will highlight the ability of Orna’s CD19 panCAR platform to generate deep and sustained B cell depletion in non-human primates across multiple doses.